Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
111 Results for "
hypoxic cell
" in MedChemExpress (MCE) Product Catalog:
Products (111)
111 Results for "hypoxic cell" in MCE Product Catalog:
Cat. No.: HY-184452
Research Areas:
BNNC is a Photomolecular glue . BNNC selectively releases (R)-CR8 (HY-18340) (a Cyclin K molecular glue) and BSS-Et in hypoxic tumor microenvironments, thereby triggering Cyclin K degradation dependent on the ubiquitin-proteasome pathway. BNNC generates ROS and singlet oxygen in hypoxic tumor cells under light irradiation. BNNC enhances DNA damage and Apoptosis through the combined effects of Cyclin K degradation and phototherapy. BNNC enhances the tumor selectivity of molecular glue via specific activation in hypoxic tumor microenvironments. BNNC can be used in breast cancer-related research .
Cat. No.: HY-P2862B
Target:
Research Areas:
α-Enolase, Human is one of three enolase isoenzymes and a glycolytic enzyme expressed in most tissues. This protein plays a key role in anaerobic metabolism under hypoxic conditions and may act as a cell surface plasminogen receptor during tissue invasion.
Cat. No.: HY-W305227
CAS No.: 923255-75-8
Target:
Research Areas:
INN-312 is a sickle hemoglobin (Hb S) inhibitor capable of penetrating red blood cell membranes. INN-312 inhibits sickling of sickle red blood cells under hypoxic conditions, increases the oxygen affinity of Hb, and moderately improves the solubility of deoxygenated Hb S. INN-312 can be used in research related to sickle cell disease .
Cat. No.: HY-182066
Target:
Research Areas:
Photosensitizer-9 is an iridium (III)-based photosensitizer with anti-melanoma activity. Photosensitizer-9 exhibits significant phototoxicity (IC50=0.98 μM) and an ideal phototoxicity index (PI=3.05). Under light irradiation, Photosensitizer-9 generates large amounts of intracellular •OH in an oxygen-independent manner. Photosensitizer-9 mediates photodynamic therapy under hypoxic conditions and synergistically activates PANoptosis (by upregulating cleaved Caspase-3, GSDMD-N, p-MLKL), ferroptosis (by disrupting the GSH-GPX4-LPO axis), apoptosis, pyroptosis and necroptosis in melanoma cells. Photosensitizer-9 induces immunogenic cell death by promoting the release of damage-associated molecular patterns under hypoxic conditions and increases the maturation rate of dendritic cells. Photosensitizer-9 reduces tumor volume in melanoma-bearing mice. Photosensitizer-9 is applicable to relevant studies on melanoma .
Cat. No.: HY-16964
CAS No.: 1269802-68-7
Target:
Research Areas:
LDHA-IN-1 is a selective, competitive LDH-A inhibitor, with Ki values of 8.9 μM (NADH assay) and 4.7 μM (Pyruvate assay) against hLDH-A. LDHA-IN-1 inhibits cancer cell proliferation under hypoxic conditions. LDHA-IN-1 can be used in the research of ovarian cancer, colorectal cancer, mesothelioma and pancreatic cancer .
Cat. No.: HY-P5345A
Research Areas:
Cardiovascular Disease Infection Neurological Disease Metabolic Disease
Cat. No.: HY-N19739
CAS No.: 131353-66-7
Category:
Target:
Cat. No.: HY-183570
CAS No.: 2813319-14-9
Research Areas:
Antitumor photosensitizer-11 is a type-I carbazole/benzindolium photosensitizer with antitumor activity. Antitumor photosensitizer-11 induces ROS generation via a type-I pathway, forming superoxide anions and hydroxyl radicals. Antitumor photosensitizer-11 triggers immunogenic cell death in cancer cells via enhanced oxidative stress. Antitumor photosensitizer-11 exhibits antiproliferative activity in normoxic and hypoxic environments, inhibits breast cancer tumor growth in vivo, and promotes dendritic cell maturation and T cell infiltration. Antitumor photosensitizer-11 can be used for the research of cancer, such as breast cancer .
Target:
Research Areas:
hCAIX/XII-IN-12 (Compound 6) is a potent and highly selective dual inhibitor of hCA IX and hCA XII, with Ki values of 8.2 and 5.6 nM respectively. hCAIX/XII-IN-12 exhibits significant anti-proliferative activity against colon cancer cells, and this activity remains effective under hypoxic conditions. hCAIX/XII-IN-12 can be used for research on colon cancer .
Cat. No.: HY-189146
Research Areas:
HDTAC EGFR Degrader-1 is an EGFR HDTAC (hypoxia-activated targeted protein degradation chimera) degrader with a DC50 of 1.76 μM. HDTAC EGFR Degrader-1 consists of a linker, a tumor hypoxia-activated group (HAG, a group that generates ROS under tumor hypoxic conditions), and an EGFR ligand. HDTAC EGFR Degrader-1 drives EGFR degradation through the proteasomal pathway. HDTAC EGFR Degrader-1 downregulates Caspase-3 under hypoxic conditions. HDTAC EGFR Degrader-1 can be used in research on non-small cell lung cancer harboring EGFR mutations (EGFR ligand: FAAH-IN-2 (HY-79511); HAG: Thalidomide-O-COOH (HY-103597); linker: NH2-PEG3 (HY-W007545)) .
Cat. No.: HY-125059
CAS No.: 865531-74-4
Target:
Research Areas:
PTC-510 Free base is a compound that selectively inhibits hypoxia-induced VEGF expression in tumor cells. PTC-510 Free base demonstrates potent activity in reducing endogenous VEGF production under hypoxic conditions. PTC-510 Free base has been shown to control tumor growth effectively while minimizing toxicity. PTC-510 Free base represents a novel therapeutic strategy to address the limitations of current anti-VEGF therapies.
Cat. No.: HY-187192
Research Areas:
TBBS-CPT is a photoactivatable prodrug that selectively accumulates in biotin receptor-positive tumor cells. TBBS-CPT responds to glutathione to break disulfide bonds, releasing Camptothecin (HY-16560) and TBBS, which exert a synergistic anticancer effect. Upon light irradiation under both normoxic and hypoxic conditions, TBBS-CPT generates ROS, including superoxide anion radicals. TBBS-CPT preferentially accumulates in mitochondria. TBBS-CPT can be used in cancer-related research .
Cat. No.: HY-116156
CAS No.: 167648-73-9
Target:
Research Areas:
SR-4554 is a probe for the measurement of tumor hypoxia. SR-4554 undergoes enzymatic single-electron reduction reactions within hypoxic cells. SR-4554 determines the 19F retention index for four commonly used mouse tumors (EMT6, SCCVII, KILT and RIF-I) through 19F MRS technique. SR-4554 can used to detect tumor Hypoxia noninvasively by 19F magnetic resonance spectroscopy ( 19F MRS) .
Cat. No.: HY-Z16784
CAS No.: 685847-78-3
Target:
Research Areas:
PX-478 free base is a multifunctional HIF-1α inhibitor with properties including radiosensitization, autophagy activation, and lipid accumulation inhibition. PX-478 free base also blocks hypoxia-induced VEGF production and regulates β-cell phenotypes under hypoxic conditions. PX-478 free base induces cell cycle arrest and DNA damage, restores autophagic function, reduces foam cell formation, and maintains glucose homeostasis. PX-478 free base is widely used in research on related diseases such as human tumors (e.g., prostate cancer), type 2 diabetes, and atherosclerosis .
Cat. No.: HY-10231R
CAS No.: 685898-44-6
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
PX-478 (Standard) is the analytical standard of PX-478 (HY-10231). This product is intended for research and analytical applications. PX-478 is a multifunctional HIF-1α inhibitor with properties including radiosensitization, autophagy activation, and lipid accumulation inhibition. PX-478 also blocks hypoxia-induced VEGF production and regulates β-cell phenotypes under hypoxic conditions. PX-478 induces cell cycle arrest and DNA damage, restores autophagic function, reduces foam cell formation, and maintains glucose homeostasis. PX-478 is widely used in research on related diseases such as human tumors (e.g., prostate cancer), type 2 diabetes, and atherosclerosis .
Cat. No.: HY-L179
39 compounds
Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells.
MCE designs a unique collection of 39 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.
Cat. No.: HY-124487
CAS No.: 1062624-71-8
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
GK-136901 is an orally active, dual Nox1/Nox4 NADPH oxidase inhibitor with a Ki of 160 nM for Nox1 and 165 nM for Nox4. GK-136901 potently blocks high glucose-induced intracellular reactive oxygen species production, p38-MAPK phosphorylation, and upregulation of TGF-β1/2 and fibronectin (fibronectin) in renal cells. GK-136901 also inhibits the proliferation of mouse pulmonary vascular cells under hypoxic conditions. GK-136901 is applicable to the research on the pathogenesis of type 2 diabetic nephropathy, high glucose-related renal lesions and pulmonary hypertension .
Cat. No.: HY-186248
CAS No.: 329719-71-3
Target:
Carbonic Anhydrase HIF/HIF Prolyl-Hydroxylase Bcl-2 Family Caspase PARP Apoptosis Reactive Oxygen Species (ROS)
Research Areas:
BCS12 is a CAIX inhibitor. BCS12 inhibits the viability of cancer cells under hypoxic conditions. BCS12 elevates ROS levels and suppresses the expression of HIF-1α and CA9. BCS12 downregulates Bcl-2, activates caspase-9, caspase-3, caspase-7 and Bax, and induces PARP cleavage and apoptosis. BCS12 reduces tumor burden, increases the number of apoptotic nuclei and restores tissue structure in rats bearing breast tumors. BCS12 can be used in research related to triple-negative breast cancer .
Cat. No.: HY-181350
Target:
Carbonic Anhydrase NAMPT Apoptosis Reactive Oxygen Species (ROS) ERK Akt DNA/RNA Synthesis Mitochondrial Metabolism
Research Areas:
CAIX/XII/NAMPT-IN-1 is a triple inhibitor of carbonic anhydrase IX/XII and nicotinamide phosphoribosyltransferase (NAMPT) with a hCA IX Ki of 78.1 nM, hCA XII Ki of 64.4 nM, and hNAMPT IC50 of 168 nM. CAIX/XII/NAMPT-IN-1 induces apoptosis, ROS accumulation, suppresses ERK/AKT signaling, inhibits DNA synthesis, and causes mitochondrial dysfunction. CAIX/XII/NAMPT-IN-1 exerts antiproliferative effects against multiple cancer cells under normoxic and hypoxic conditions. CAIX/XII/NAMPT-IN-1 can be used for the research of cancer, such as renal carcinoma, glioblastoma and colorectal cancer .
Cat. No.: HY-179034
Target:
Research Areas:
CAIX/XII-IN-16 (Compound 5d) is a selective inhibitor of CA IX/XII and c-Met. CAIX/XII-IN-16‘s Ki values for hCA IX, hCA XII and CA I are 10.6, 31.8 and 2361 nM respectively, and its IC50 value for c-Met is 0.49 μM. CAIX/XII-IN-16 exhibits significantly enhanced cytotoxicity against colon cancer cells under hypoxic conditions. CAIX/XII-IN-16 causes cell cycle arrest and induces apoptosis (apoptosis). CAIX/XII-IN-16 significantly enhances the efficacy of Oxaliplatin (HY-17371) and 5-Fluorouracil (HY-90006). CAIX/XII-IN-16 can be used for studies on chemotherapy resistance related to hypoxia .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
